Astria Therapeutics Z Score

Delisted . USA . 
Delisted Stock . Astria Therapeutics
ATXSDelisted Delisted Stock  USD 5,874  0.00  0.00%   

The Altman Z-Score provides a single-number summary of financial condition from five weighted ratios. Astria Therapeutics's Z-Score stands at 77.76 based on the latest filings, well above conventional distress thresholds, indicating exceptionally strong financial positioning within the model framework. The elevated score is driven in part by Astria Therapeutics's high market capitalization relative to total debt, which materially increases the model output.

Astria Therapeutics Altman Z-Score
    
  77.76  

Interpreting Astria Therapeutics Z-Score

Above 3.0: typically indicates stronger condition
2.7 to 3.0: transition interval
1.8 to 2.7: watch interval
Below 1.8: higher distress probability interval

Why Monitor Z-Score for Astria Therapeutics

The model’s value lies in its simplicity and empirical track record. It collapses five distinct dimensions of financial health into a single number that can be compared across companies, sectors, and time periods with a consistent interpretation framework.

Astria Therapeutics has a market cap of 718.13 million, an operating margin of -48.31% (TTM), current ratio of 19.87. These fundamentals are most informative when tracked over multiple reporting periods. Broader economic conditions can influence Astria Therapeutics's company valuation - related indicators include signals in real.
  

Astria Therapeutics' Z-Score is a linear multi-factor model designed to assess financial distress risk using a weighted combination of accounting ratios. Its interpretation depends on industry context and may be less directly comparable for asset-light business models. The model uses five fundamental business ratios that are weighted according to the algorithm of Professor Edward Altman who developed it in the late 1960s at New York University.

Z Score

 = 

Sum Of

5 Factors

ComponentValueWeightWeighted
Working Capital / Total Assets315.51 million / 342.36 million1.21.11
Retained Earnings / Total Assets-674.79 million / 342.36 million1.4-2.76
EBITDA / Total Assets-111.56 million / 342.36 million3.3-1.08
Market Cap / Total Debt718.13 million / 5.35 million0.680.49
Revenue / Total Assets
 / 342.36 million0.9990.0
Z-Score
77.76
Note: Altman's original specification uses EBIT for the third factor. Using EBITDA instead of EBIT may overstate T3, potentially inflating the overall Z-Score relative to the original specification.
Competition

Fundamental Drivers Relationships

Did You Try This?

Run Cryptocurrency Center Now

   

Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
All  Next Launch Module

Important Fundamentals

Return On Equity TTM-0.43
Return On Asset TTM-0.27
Operating Margin TTM-48.31
Current Valuation590.19 M
Shares Outstanding57.08 M
Shares Owned By Insiders0.48 %
Shares Owned By Institutions94.90 %
Number Of Shares Shorted5.75 M
Price To Book TTM5.21 X
Price To Sales TTM1,017 X
Gross Profit TTM706 K
EBITDA TTM-111.56 M
Net Income TTM-94.26 M
Cash And Equivalents TTM102.48 M
Cash Per Share TTM7.87 X
Total Debt TTM5.35 M
Debt To Equity TTM0.01 %
Current Ratio TTM19.87 X
Book Value Per Share TTM2.44 X
Cash Flow From Operations TTM-81.21 M
Short Ratio TTM4.70 X
Earnings Per Share-2.14 X
Target Price13.0
Number Of Employees78
Trailing Beta0.019
Market Capitalization TTM718.13 M
Total Asset TTM342.36 M
Retained Earnings TTM-674.79 M
Working Capital TTM315.51 M
Net Asset342.36 M

Altman Z-Score Methodology & Financial Data

The Z-Score for Astria Therapeutics integrates short-term liquidity with longer-term solvency and profitability indicators. Scores above 2.99 fall in the safe zone, between 1.81 and 2.99 in the grey zone, and below 1.81 in the distress zone. For distress analysis, Astria Therapeutics shows current ratio of 19.87, debt-to-equity of 0.01, working capital of 315.51 million.

Astria Therapeutics data is compiled from periodic company reporting and market reference feeds and standardized for comparability.

Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board


 
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.